Australia's most trusted
source of pharma news
Wednesday, 05 February 2025
Posted 23 January 2024 PM
Samsung Bioepis' Brenzys has been crowned the top-earning PBS listed biosimilar brand, however, biosimilars of AbbVie's Humira combined cost the government more overall.
According to the latest PBS Expenditure and Prescriptions report for the 2022-23 financial year, Brenzys - a biosimilar of Pfizer's Enbrel - cost the government $41.8 million over the reported period.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.